- Home
- DCTH vs SGHT Comparison
DCTH vs SGHT Comparison
Compare DCTH & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DCTH
- SGHT
- Stock Information
- Founded
- DCTH 1988
- SGHT 2011
- Country
- DCTH United States
- SGHT United States
- Employees
- DCTH N/A
- SGHT N/A
- Industry
- DCTH Medical/Dental Instruments
- SGHT Medical Specialities
- Sector
- DCTH Health Care
- SGHT Health Care
- Exchange
- DCTH Nasdaq
- SGHT Nasdaq
- Market Cap
- DCTH 379.5M
- SGHT 304.4M
- IPO Year
- DCTH N/A
- SGHT 2021
- Fundamental
- Price
- DCTH $11.87
- SGHT $3.87
- Analyst Decision
- DCTH Strong Buy
- SGHT Buy
- Analyst Count
- DCTH 4
- SGHT 7
- Target Price
- DCTH $21.50
- SGHT $6.58
- AVG Volume (30 Days)
- DCTH 489.1K
- SGHT 249.8K
- Earning Date
- DCTH 11-08-2024
- SGHT 11-07-2024
- Dividend Yield
- DCTH N/A
- SGHT N/A
- EPS Growth
- DCTH N/A
- SGHT N/A
- EPS
- DCTH N/A
- SGHT N/A
- Revenue
- DCTH $22,644,000.00
- SGHT $79,543,000.00
- Revenue This Year
- DCTH $1,605.13
- SGHT $2.18
- Revenue Next Year
- DCTH $111.67
- SGHT $8.14
- P/E Ratio
- DCTH N/A
- SGHT N/A
- Revenue Growth
- DCTH 945.91
- SGHT N/A
- 52 Week Low
- DCTH $2.84
- SGHT $2.58
- 52 Week High
- DCTH $12.88
- SGHT $8.45
- Technical
- Relative Strength Index (RSI)
- DCTH 61.82
- SGHT 39.20
- Support Level
- DCTH $11.42
- SGHT $3.65
- Resistance Level
- DCTH $12.79
- SGHT $4.11
- Average True Range (ATR)
- DCTH 0.66
- SGHT 0.19
- MACD
- DCTH 0.15
- SGHT 0.06
- Stochastic Oscillator
- DCTH 74.17
- SGHT 27.50
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.